While efforts to boost transparency in the health care industry via recent proposals is beneficial, “transparency loses its efficacy when applied piecemeal,” Brodeur Partners’ Lauren Levinson writes in a recent article published on MM&M.
As drug pricing takes center stage in Q4 2018, the government has recently pushed for incremental transparency in “discrete, well-defined segments of the healthcare ecosystem.”
Levinson cites a recent proposal from the Trump administration to align some drugs covered under Medicare Part B with prices paid overseas, as well as a bid to display list prices in direct-to-consumer drug advertisements.
“What continues to be lost in various healthcare proposals is that transparency loses its efficacy when applied piecemeal,” Levinson writes. “With greater transparency of the cost and sale price of a drug must also come greater transparency of the inputs, ecosystem, and risk investment on which drug development relies.”